SCOC
gene geneOn this page
Also known as HRIHFB2072SCOCOUNC-69
Summary
SCOC (short coiled-coil protein, HGNC:20335) is a protein-coding gene on chromosome 4q31.1, encoding Short coiled-coil protein (Q9UIL1). Positive regulator of amino acid starvation-induced autophagy.
This gene encodes a short coiled-coiled domain-containing protein that localizes to the Golgi apparatus. The encoded protein interacts with ADP-ribosylation factor-like proteins. Pseudogenes of this gene are found on chromosomes 1 and 14. Alternative splicing results in multiple transcript variants.
Source: NCBI Gene 60592 — RefSeq curated summary.
At a glance
- GWAS associations: 5
- Clinical variants (ClinVar): 28 total
- MANE Select transcript:
NM_001153484
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:20335 |
| Approved symbol | SCOC |
| Name | short coiled-coil protein |
| Location | 4q31.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | HRIHFB2072, SCOCO, UNC-69 |
| Ensembl gene | ENSG00000153130 |
| Ensembl biotype | protein_coding |
| Entrez | 60592 |
Gene structure
Transcript identifiers
Ensembl transcripts: 34 — 34 protein_coding
ENST00000338517, ENST00000394203, ENST00000394205, ENST00000502535, ENST00000506322, ENST00000506597, ENST00000510586, ENST00000512749, ENST00000608372, ENST00000860187, ENST00000860188, ENST00000860189, ENST00000860190, ENST00000860191, ENST00000860192, ENST00000860193, ENST00000860194, ENST00000860195, ENST00000860196, ENST00000860197, ENST00000860198, ENST00000860199, ENST00000860200, ENST00000860201, ENST00000860202, ENST00000860203, ENST00000924238, ENST00000924239, ENST00000924240, ENST00000958255, ENST00000958256, ENST00000958257, ENST00000958258, ENST00000958259
RefSeq mRNA: 8 — MANE Select: NM_001153484
NM_001153446, NM_001153484, NM_001153552, NM_001153585, NM_001153635, NM_001153663, NM_001153690, NM_032547
CCDS: CCDS3750, CCDS54806, CCDS54807
Canonical transcript exons
ENST00000608372 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003707307 | 140379569 | 140379652 |
| ENSE00003707441 | 140373646 | 140373717 |
| ENSE00003708448 | 140380962 | 140385728 |
| ENSE00003709164 | 140379121 | 140379192 |
Expression profiles
Bgee: expression breadth ubiquitous, 254 present calls, max score 99.71.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 44.0192 / max 1240.9486, expressed in 1791 samples.
FANTOM5 promoters (7 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 49793 | 36.2164 | 1777 |
| 49794 | 7.0237 | 1556 |
| 49792 | 0.4810 | 66 |
| 49791 | 0.1412 | 47 |
| 49786 | 0.1009 | 47 |
| 49785 | 0.0442 | 18 |
| 49784 | 0.0118 | 2 |
Top tissues by expression
256 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| lateral nuclear group of thalamus | UBERON:0002736 | 99.71 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 99.54 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 99.40 | gold quality |
| dorsal plus ventral thalamus | UBERON:0001897 | 99.19 | gold quality |
| superior vestibular nucleus | UBERON:0007227 | 99.16 | gold quality |
| pons | UBERON:0000988 | 99.15 | gold quality |
| lateral globus pallidus | UBERON:0002476 | 99.14 | gold quality |
| subthalamic nucleus | UBERON:0001906 | 99.11 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 99.05 | gold quality |
| medulla oblongata | UBERON:0001896 | 98.95 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 98.91 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 98.75 | gold quality |
| hypothalamus | UBERON:0001898 | 98.67 | gold quality |
| spinal cord | UBERON:0002240 | 98.65 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 98.60 | gold quality |
| dorsal root ganglion | UBERON:0000044 | 98.59 | gold quality |
| cerebellar vermis | UBERON:0004720 | 98.58 | gold quality |
| midbrain | UBERON:0001891 | 98.53 | gold quality |
| substantia nigra | UBERON:0002038 | 98.52 | gold quality |
| myocardium | UBERON:0002349 | 98.40 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 98.33 | gold quality |
| inferior vagus X ganglion | UBERON:0005363 | 98.31 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 98.27 | gold quality |
| islet of Langerhans | UBERON:0000006 | 98.25 | gold quality |
| prefrontal cortex | UBERON:0000451 | 98.22 | gold quality |
| trigeminal ganglion | UBERON:0001675 | 98.21 | gold quality |
| ventral tegmental area | UBERON:0002691 | 98.16 | gold quality |
| kidney epithelium | UBERON:0004819 | 98.14 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 98.11 | gold quality |
| nucleus accumbens | UBERON:0001882 | 97.94 | gold quality |
Single-cell (SCXA)
Detected in 4 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-10 | yes | 23.74 |
| E-MTAB-7316 | yes | 13.15 |
| E-HCAD-5 | no | 8.45 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
113 targeting SCOC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6876-5P | 100.00 | 67.68 | 2126 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-4476 | 100.00 | 68.18 | 2030 |
| HSA-MIR-200B-3P | 100.00 | 73.31 | 2693 |
| HSA-MIR-200C-3P | 100.00 | 73.35 | 2685 |
| HSA-MIR-429 | 100.00 | 73.44 | 2698 |
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-181A-5P | 99.99 | 72.96 | 2995 |
| HSA-MIR-181B-5P | 99.99 | 72.97 | 2996 |
| HSA-MIR-181C-5P | 99.99 | 72.95 | 2996 |
| HSA-MIR-181D-5P | 99.99 | 73.04 | 2997 |
| HSA-MIR-548AW | 99.99 | 72.57 | 3559 |
| HSA-MIR-4803 | 99.98 | 71.99 | 3117 |
| HSA-MIR-4482-3P | 99.98 | 72.50 | 3147 |
| HSA-MIR-302C-5P | 99.97 | 72.56 | 3642 |
| HSA-MIR-507 | 99.97 | 70.11 | 1915 |
| HSA-MIR-1468-3P | 99.96 | 72.74 | 3797 |
| HSA-MIR-557 | 99.96 | 70.01 | 1640 |
| HSA-MIR-335-3P | 99.93 | 73.36 | 4958 |
| HSA-MIR-497-5P | 99.92 | 71.83 | 2674 |
| HSA-MIR-450B-5P | 99.92 | 71.48 | 3175 |
| HSA-MIR-1305 | 99.91 | 71.43 | 3443 |
| HSA-MIR-15A-5P | 99.90 | 72.80 | 2787 |
| HSA-MIR-15B-5P | 99.90 | 72.78 | 2798 |
| HSA-MIR-16-5P | 99.90 | 72.80 | 2780 |
| HSA-MIR-195-5P | 99.90 | 72.81 | 2805 |
| HSA-MIR-3686 | 99.90 | 70.53 | 2432 |
| HSA-MIR-4753-3P | 99.90 | 71.03 | 3786 |
Literature-anchored findings (GeneRIF, showing 5)
- The identification of SCOC and WAC as novel regulatory proteins with diverse functions in autophagy contributes towards a fuller understanding of autophagosome formation. (PMID:22354037)
- SCOC forms a stable homogeneous complex with the coiled coil domain of FEZ1. SCOC dimerization and the SCOC surface residue R117 are important for this interaction. (PMID:24098481)
- Studies indicate that FEZ1 (fasciculation and elongation protein zeta 1), SCOCO (short coiled-coil protein) and kinesins (kinesin heavy chain) are involved in biological transport process. (PMID:24116125)
- SCOC SNPs were associated with lifetime cannabis use, but the association did not reach genome-wide significance. [Meta-Analysis] (PMID:27023175)
- Phosphorylation of the LIR Domain of SCOC Modulates ATG8 Binding Affinity and Specificity. (PMID:33845085)
Cross-species orthologs
6 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | scocb | ENSDARG00000002217 |
| danio_rerio | scoca | ENSDARG00000087333 |
| mus_musculus | Scoc | ENSMUSG00000063253 |
| rattus_norvegicus | Scoc | ENSRNOG00000003853 |
| drosophila_melanogaster | CG5934 | FBGN0039505 |
| caenorhabditis_elegans | WBGENE00006802 |
Protein
Protein identifiers
Short coiled-coil protein — Q9UIL1 (reviewed: Q9UIL1)
All UniProt accessions (3): Q9UIL1, A0A0C4DGB0, A0A804E055
UniProt curated annotations — full annotation on UniProt →
Function. Positive regulator of amino acid starvation-induced autophagy.
Subunit / interactions. Homodimer. Interacts with ARL1, ARL2 and ARL3. Directly interacts with FEZ1 and UVRAG. The interaction with UVRAG is reduced by amino acid starvation, but the complex is stabilized in the presence of FEZ1. Interacts with NRBF2.
Subcellular location. Golgi apparatus membrane. Golgi apparatus. trans-Golgi network. Cytoplasm. Cytosol.
Tissue specificity. Widely expressed with highest levels in brain, heart and skeletal muscle.
Similarity. Belongs to the SCOC family.
Isoforms (4)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9UIL1-1 | 1 | yes |
| Q9UIL1-2 | 2 | |
| Q9UIL1-3 | 3 | |
| Q9UIL1-4 | 4 |
RefSeq proteins (8): NP_001146918, NP_001146956, NP_001147024, NP_001147057, NP_001147107, NP_001147135, NP_001147162, NP_115936 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR019357 | SCOC | Family |
Pfam: PF10224
UniProt features (15 total): mutagenesis site 5, splice variant 4, sequence conflict 2, chain 1, coiled-coil region 1, turn 1, helix 1
Structure
Experimental structures (PDB)
2 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 7AA7 | X-RAY DIFFRACTION | 1.45 |
| 4BWD | X-RAY DIFFRACTION | 2.7 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9UIL1-F1 | 66.24 | 0.25 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Mutagenesis-validated functional residues (5):
| Position | Phenotype |
|---|---|
| 132 | causes tetramerization and loss of interaction with fez1; when associated with l-125. |
| 93 | causes trimerization and impairs interaction with fez1 coiled coil but does not impair interaction with full-length fez1 |
| 97 | causes trimerization and impairs interaction with fez1 coiled coil but does not impair interaction with full-length fez1 |
| 117 | impairs interaction with fez1 coiled coil but does not impair interaction with full-length fez1. |
| 125 | causes tetramerization and loss of interaction with fez1; when associated with v-132. |
Function
Pathways and Gene Ontology
Reactome pathways
4 pathways
| ID | Pathway |
|---|---|
| R-HSA-6811440 | Retrograde transport at the Trans-Golgi-Network |
| R-HSA-199991 | Membrane Trafficking |
| R-HSA-5653656 | Vesicle-mediated transport |
| R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic |
MSigDB gene sets: 169 (showing top):
RRAGTTGT_UNKNOWN, GOBP_REGULATION_OF_AUTOPHAGY, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, REACTOME_MEMBRANE_TRAFFICKING, AAAYRNCTG_UNKNOWN, GOBP_MACROAUTOPHAGY, SRF_Q5_01, SRF_01, MARTINEZ_RB1_TARGETS_UP, SRF_C, GOCC_TRANS_GOLGI_NETWORK, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS, BACH2_01
GO Biological Process (2): positive regulation of macroautophagy (GO:0016239), regulation of protein complex stability (GO:0061635)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (8): Golgi membrane (GO:0000139), nucleoplasm (GO:0005654), Golgi apparatus (GO:0005794), cytosol (GO:0005829), cytoplasm (GO:0005737), endosome (GO:0005768), trans-Golgi network (GO:0005802), membrane (GO:0016020)
Reactome top-level categories
Rollup of top-3 pathways:
| Category | Pathways |
|---|---|
| Intra-Golgi and retrograde Golgi-to-ER traffic | 1 |
| Vesicle-mediated transport | 1 |
| Membrane Trafficking | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 4 |
| cytoplasm | 2 |
| endomembrane system | 2 |
| positive regulation of autophagy | 1 |
| macroautophagy | 1 |
| regulation of macroautophagy | 1 |
| regulation of biological quality | 1 |
| binding | 1 |
| Golgi apparatus | 1 |
| bounding membrane of organelle | 1 |
| nuclear lumen | 1 |
| intracellular membrane-bounded organelle | 1 |
| intracellular anatomical structure | 1 |
| cytoplasmic vesicle | 1 |
| Golgi apparatus subcompartment | 1 |
Protein interactions and networks
STRING
826 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SCOC | FEZ1 | Q99689 | 820 |
| SCOC | KCNT2 | Q6UVM3 | 680 |
| SCOC | WAC | Q9BTA9 | 663 |
| SCOC | ARL3 | P36405 | 636 |
| SCOC | ULK1 | O75385 | 584 |
| SCOC | FEZ2 | Q9UHY8 | 566 |
| SCOC | RAB3GAP1 | Q15042 | 561 |
| SCOC | UVRAG | Q9P2Y5 | 552 |
| SCOC | C2orf80 | Q0P641 | 527 |
| SCOC | RAB3GAP2 | Q9H2M9 | 527 |
| SCOC | TTC12 | Q9H892 | 525 |
| SCOC | MGAT4D | A6NG13 | 506 |
| SCOC | FAM89B | Q8N5H3 | 506 |
| SCOC | ARFRP1 | Q13795 | 505 |
| SCOC | SLC66A2 | Q8N2U9 | 497 |
IntAct
39 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| FEZ1 | SCOC | psi-mi:“MI:0915”(physical association) | 0.700 |
| SCOC | FEZ1 | psi-mi:“MI:0403”(colocalization) | 0.700 |
| SCHIP1 | SCOC | psi-mi:“MI:0915”(physical association) | 0.690 |
| SCOC | SCHIP1 | psi-mi:“MI:0915”(physical association) | 0.690 |
| TCF4 | SCOC | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRT40 | SCOC | psi-mi:“MI:0915”(physical association) | 0.560 |
| SCOC | TCF4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| EPB41L3 | AP3B1 | psi-mi:“MI:0914”(association) | 0.530 |
| Srgap2 | SCOC | psi-mi:“MI:0915”(physical association) | 0.400 |
| SCOC | MAPK8 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ORF17 | KPNA5 | psi-mi:“MI:0914”(association) | 0.350 |
| ORF17.5 | WWP2 | psi-mi:“MI:0914”(association) | 0.350 |
| ESR1 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| H2BC21 | SMCHD1 | psi-mi:“MI:0914”(association) | 0.350 |
| HMGA1 | SUPT5H | psi-mi:“MI:0914”(association) | 0.350 |
| MAPRE1 | SCAMP1 | psi-mi:“MI:0914”(association) | 0.350 |
| NUMA1 | SHANK3 | psi-mi:“MI:0914”(association) | 0.350 |
| RPS6KA4 | H1-0 | psi-mi:“MI:0914”(association) | 0.350 |
| SCHIP1 | VWA8 | psi-mi:“MI:0914”(association) | 0.350 |
| FEZ1 | POLRMT | psi-mi:“MI:0914”(association) | 0.350 |
| SCOC | SNAPIN | psi-mi:“MI:0914”(association) | 0.350 |
| BFSP2 | NEK2 | psi-mi:“MI:0914”(association) | 0.350 |
| FEZ1 | KCNN4 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (82): SCOC (Two-hybrid), KRT40 (Two-hybrid), SCOC (Affinity Capture-MS), SCOC (Co-fractionation), SCOC (Co-fractionation), SCOC (Two-hybrid), SCHIP1 (Affinity Capture-MS), C21orf91 (Affinity Capture-MS), FEZ2 (Affinity Capture-MS), SCOC (Affinity Capture-MS), TBC1D30 (Affinity Capture-MS), HEATR5A (Affinity Capture-MS), SASS6 (Affinity Capture-MS), GCC1 (Affinity Capture-MS), NRBF2 (Affinity Capture-MS)
ESM2 similar proteins: A4Q9F3, A8IHN8, D3YYI7, M0R7T9, O09112, O60347, O88751, P51509, Q09YL6, Q0IHH1, Q13202, Q13505, Q14190, Q147X3, Q17QD9, Q3TZ87, Q3UPL5, Q3V1H9, Q5TGI4, Q5VUJ9, Q5VV17, Q5XI57, Q61079, Q6A039, Q6PDS0, Q6ZVT0, Q7Z7K6, Q80UW0, Q86YJ5, Q8C4U2, Q8CES0, Q8N554, Q8N8J7, Q8TC41, Q8TDR2, Q8WWW0, Q96AQ8, Q96ET8, Q96KN8, Q96MM7
Diamond homologs: A8NJZ7, Q08BG7, Q5RJZ6, Q5XJK1, Q78YZ6, Q9UIL1
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
28 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 20 |
| Likely benign | 2 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2020 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 4:140257406:GGAAG:G | donor_gain | 1.0000 |
| 4:140257407:GAAG:G | donor_gain | 1.0000 |
| 4:140257407:GAAGG:G | donor_gain | 1.0000 |
| 4:140257411:G:GG | donor_gain | 1.0000 |
| 4:140343705:ATAGG:A | donor_loss | 1.0000 |
| 4:140343706:TAGG:T | donor_loss | 1.0000 |
| 4:140343707:AGGTA:A | donor_loss | 1.0000 |
| 4:140343708:GGTAA:G | donor_loss | 1.0000 |
| 4:140343709:GTAAG:G | donor_loss | 1.0000 |
| 4:140343710:T:A | donor_loss | 1.0000 |
| 4:140379567:A:AG | acceptor_gain | 1.0000 |
| 4:140379568:G:GG | acceptor_gain | 1.0000 |
| 4:140379568:GC:G | acceptor_gain | 1.0000 |
| 4:140379568:GCA:G | acceptor_gain | 1.0000 |
| 4:140379648:TGAAG:T | donor_loss | 1.0000 |
| 4:140379650:AAGG:A | donor_loss | 1.0000 |
| 4:140379651:AGGT:A | donor_loss | 1.0000 |
| 4:140379652:GGTT:G | donor_loss | 1.0000 |
| 4:140379653:G:GA | donor_loss | 1.0000 |
| 4:140379654:T:A | donor_loss | 1.0000 |
| 4:140380957:T:G | acceptor_gain | 1.0000 |
| 4:140380957:TATA:T | acceptor_loss | 1.0000 |
| 4:140380958:ATAG:A | acceptor_loss | 1.0000 |
| 4:140380959:T:G | acceptor_gain | 1.0000 |
| 4:140380959:TAG:T | acceptor_loss | 1.0000 |
| 4:140380960:A:AG | acceptor_gain | 1.0000 |
| 4:140380960:A:C | acceptor_loss | 1.0000 |
| 4:140380961:G:GA | acceptor_gain | 1.0000 |
| 4:140380961:G:GT | acceptor_loss | 1.0000 |
| 4:140380961:GAT:G | acceptor_gain | 1.0000 |
AlphaMissense
1038 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 4:140381069:T:C | F149L | 1.000 |
| 4:140381071:T:A | F149L | 1.000 |
| 4:140381071:T:G | F149L | 1.000 |
| 4:140379635:T:C | L107P | 0.999 |
| 4:140380965:T:C | L114P | 0.999 |
| 4:140381007:T:C | L128P | 0.999 |
| 4:140381028:T:A | L135H | 0.999 |
| 4:140381036:T:C | Y138H | 0.999 |
| 4:140381037:A:G | Y138C | 0.999 |
| 4:140381049:T:C | L142P | 0.999 |
| 4:140381070:T:G | F149C | 0.999 |
| 4:140379614:T:C | L100P | 0.998 |
| 4:140379647:T:A | L111H | 0.998 |
| 4:140380986:T:A | V121D | 0.998 |
| 4:140381001:T:C | L126P | 0.998 |
| 4:140381018:A:G | N132D | 0.998 |
| 4:140381020:C:A | N132K | 0.998 |
| 4:140381020:C:G | N132K | 0.998 |
| 4:140381040:T:A | I139K | 0.998 |
| 4:140381049:T:A | L142H | 0.998 |
| 4:140380965:T:A | L114H | 0.997 |
| 4:140380982:G:C | A120P | 0.997 |
| 4:140380990:G:C | K122N | 0.997 |
| 4:140380990:G:T | K122N | 0.997 |
| 4:140381012:T:C | S130P | 0.997 |
| 4:140381069:T:G | F149V | 0.997 |
| 4:140381070:T:C | F149S | 0.997 |
| 4:140379623:A:C | Q103P | 0.996 |
| 4:140379647:T:C | L111P | 0.996 |
| 4:140380999:T:A | N125K | 0.996 |
dbSNP variants (sampled 300 via entrez): RS1000005162 (4:140294675 CTA>C), RS1000012045 (4:140340602 G>T), RS1000045911 (4:140296018 G>C,T), RS1000064272 (4:140287944 G>A), RS1000078209 (4:140341822 C>T), RS1000101398 (4:140289013 A>G), RS1000114731 (4:140313542 G>A), RS1000152837 (4:140381174 A>G), RS1000153980 (4:140313569 C>T), RS1000200570 (4:140270995 TTC>T), RS1000203510 (4:140264563 A>C), RS1000223101 (4:140361711 A>C), RS1000320584 (4:140374160 G>A), RS1000323095 (4:140359992 G>A), RS10003754 (4:140329988 G>A,T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
5 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST007327_112 | Smoking status (ever vs never smokers) | 2.000000e-09 |
| GCST007327_138 | Smoking status (ever vs never smokers) | 4.000000e-09 |
| GCST010725_4 | Malaria | 4.000000e-10 |
| GCST010725_84 | Malaria | 7.000000e-11 |
| GCST010725_89 | Malaria | 7.000000e-11 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004318 | smoking behavior |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
47 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Air Pollutants | affects expression, increases abundance, decreases expression | 3 |
| bisphenol A | affects cotreatment, increases methylation, decreases methylation, increases expression | 2 |
| sodium arsenite | decreases expression, affects cotreatment, increases abundance, increases expression | 2 |
| Smoke | decreases expression, increases abundance | 2 |
| bisphenol F | affects cotreatment, decreases expression | 1 |
| dicrotophos | decreases expression | 1 |
| bufotalin | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| titanium dioxide | increases methylation | 1 |
| manganese chloride | increases abundance, increases expression, affects cotreatment | 1 |
| beta-methylcholine | affects expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| chloropicrin | increases expression | 1 |
| 4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide | decreases expression | 1 |
| eprenetapopt | affects expression, affects reaction | 1 |
| bisphenol S | increases methylation | 1 |
| jinfukang | decreases expression | 1 |
| picoxystrobin | decreases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Zoledronic Acid | increases expression | 1 |
| Fulvestrant | affects cotreatment, increases methylation | 1 |
| Vorinostat | increases expression | 1 |
| Antimycin A | decreases expression | 1 |
| Arsenic | affects cotreatment, increases abundance, increases expression | 1 |
| Benzo(a)pyrene | affects methylation, increases methylation | 1 |
| Calcitriol | increases expression | 1 |
| Dexamethasone | affects cotreatment, decreases expression | 1 |
| Estradiol | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.